ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of card
Go back to ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of card| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1103.69 +5.12 (0.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1098.57 | 52 Week High | $88.16 | |||
| Open | $1112.24 | 52 Week Low | $67.88 | |||
| Day High | $1119.45 | P/E | 255.48 | |||
| Day Low | $1093.15 | EPS | $4.32 | |||
| Volume | 2,161,268 | |||||
